CD57 Expression in Incidental, Clinically Manifest, and Metastatic Carcinoma of the ProstateReportar como inadecuado

CD57 Expression in Incidental, Clinically Manifest, and Metastatic Carcinoma of the Prostate - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BioMed Research International - Volume 2014 2014, Article ID 356427, 9 pages -

Research Article

Institute of Pathology, University Medicine Rostock, Strempelstraße 14, 18055 Rostock, Germany

Institute of Pathology, University of Bonn, Germany

Martini Clinic, University Hospital Hamburg-Eppendorf, Germany

Department of Urology, Charité University Hospital Berlin and Berlin Institute for Urologic Research, Germany

Institute of Pathology, Stendal, Germany

Institute of Pathology, University of Heidelberg, Germany

Institute of Pathology, University Hospital Hamburg-Eppendorf, Germany

Received 2 April 2014; Accepted 7 May 2014; Published 22 May 2014

Academic Editor: Ralph Buttyan

Copyright © 2014 Holger Wangerin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objectives. CD57 is normally found on NK-cells, but little is known about its expression in prostatic tissue. Methods. We investigated CD57 expression by immunohistochemistry using tissue microarrays containing 3262 prostate cancers PCa, lymph node metastases, and benign prostatic tissue. The results were compared with clinical and pathological parameters. Results. Overall, 87% of PCa showed a moderate or strong expression of CD57. There was no significant difference to corresponding benign prostatic tissue. CD57 was increasingly lost from incidental over clinically manifest cancers to metastases. It correlated significantly with Gleason grade and pT-category, but not with PSA tissue expression. Loss of CD57 expression was an independent risk factor for PSA recurrence after prostatectomy in a multivariate Cox regression analysis. In standard sections, CD57 expression was heterogeneous, especially in large, high-grade PCa. Conclusions. There is a peculiar expression of CD57 in PCa and benign prostatic tissue. CD57 loss is associated with tumor dedifferentiation and tumor size. However, the use of this marker for prognostic purposes is hampered by its heterogeneous expression.

Autor: Holger Wangerin, Glen Kristiansen, Thorsten Schlomm, Carsten Stephan, Sven Gunia, Annette Zimpfer, Wilko Weichert, Guido Sa



Documentos relacionados